Aptamer Group (APTA) Competitors GBX 0.71 +0.08 (+12.38%) As of 12:32 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsBuy This Stock APTA vs. ETX, SBTX, COS, C4XD, DDDD, FUM, TRX, SAR, AREC, and OKYOShould you be buying Aptamer Group stock or one of its competitors? The main competitors of Aptamer Group include e-therapeutics (ETX), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Futura Medical (FUM), Tissue Regenix Group (TRX), Sareum (SAR), Arecor Therapeutics (AREC), and OKYO Pharma (OKYO). These companies are all part of the "biotechnology" industry. Aptamer Group vs. Its Competitors e-therapeutics SkinBioTherapeutics Collagen Solutions plc (COS.L) C4X Discovery 4D pharma Futura Medical Tissue Regenix Group Sareum Arecor Therapeutics OKYO Pharma Aptamer Group (LON:APTA) and e-therapeutics (LON:ETX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability. Which has stronger valuation and earnings, APTA or ETX? e-therapeutics has lower revenue, but higher earnings than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptamer Group£4.12M3.42-£14.17M-£0.71-0.99e-therapeutics£295K0.00-£10.06M-£0.02N/A Is APTA or ETX more profitable? e-therapeutics has a net margin of 0.00% compared to Aptamer Group's net margin of -343.95%. e-therapeutics' return on equity of -38.75% beat Aptamer Group's return on equity.Company Net Margins Return on Equity Return on Assets Aptamer Group-343.95% -205.63% -44.96% e-therapeutics N/A -38.75%-29.10% Does the media refer more to APTA or ETX? In the previous week, Aptamer Group's average media sentiment score of 0.49 beat e-therapeutics' score of 0.00 indicating that Aptamer Group is being referred to more favorably in the media. Company Overall Sentiment Aptamer Group Neutral e-therapeutics Neutral Do insiders and institutionals have more ownership in APTA or ETX? 11.7% of Aptamer Group shares are owned by institutional investors. Comparatively, 26.5% of e-therapeutics shares are owned by institutional investors. 13.2% of Aptamer Group shares are owned by insiders. Comparatively, 59.4% of e-therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility and risk, APTA or ETX? Aptamer Group has a beta of -0.52, meaning that its share price is 152% less volatile than the S&P 500. Comparatively, e-therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Summarye-therapeutics beats Aptamer Group on 8 of the 11 factors compared between the two stocks. Get Aptamer Group News Delivered to You Automatically Sign up to receive the latest news and ratings for APTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APTA vs. The Competition Export to ExcelMetricAptamer GroupBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£14.07M£137.09M£5.82B£3.22BDividend YieldN/A3.74%3.84%5.04%P/E Ratio-0.993.8731.15164.63Price / Sales3.424,053.59475.15310,107.36Price / CashN/A13.1937.1527.93Price / Book3.3146.309.115.90Net Income-£14.17M-£90.99M£3.26B£5.89B7 Day Performance5.04%0.61%2.11%48.33%1 Month Performance83.42%3.58%5.12%49.98%1 Year Performance191.36%197.78%31.25%127.65% Aptamer Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APTAAptamer GroupN/AGBX 0.71+12.4%N/A+162.5%£14.07M£4.12M-0.9937News CoverageGap UpHigh Trading VolumeETXe-therapeuticsN/AN/AN/AN/A£52.59M£295K-450.0035High Trading VolumeSBTXSkinBioTherapeuticsN/AGBX 14.17+1.2%N/A+17.9%£32.36M£1.56M-8.7111COSCollagen Solutions plc (COS.L)N/AN/AN/AN/A£30.99M£4.01M-8.283,350C4XDC4X DiscoveryN/AN/AN/AN/A£30.27M£24.68M300.0049High Trading VolumeDDDD4D pharmaN/AN/AN/AN/A£30.05M£718K-1.08106FUMFutura MedicalN/AGBX 9.40-4.7%N/A-74.5%£29.30M£8.68M-7.7512Gap DownTRXTissue Regenix GroupN/AGBX 29.80+2.8%N/A-53.6%£26.87M£31.98M-30.77120Gap UpSARSareumN/AGBX 19.70+2.3%N/A-11.2%£24.61MN/A-4.673,211ARECArecor TherapeuticsN/AGBX 62.38-1.8%N/A-27.3%£23.55M£6.04M-2.2010OKYOOKYO PharmaN/AN/AN/AN/A£23.24MN/A-140.007Gap Down Related Companies and Tools Related Companies e-therapeutics Alternatives SkinBioTherapeutics Alternatives Collagen Solutions plc (COS.L) Alternatives C4X Discovery Alternatives 4D pharma Alternatives Futura Medical Alternatives Tissue Regenix Group Alternatives Sareum Alternatives Arecor Therapeutics Alternatives OKYO Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:APTA) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptamer Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptamer Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access